Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Impella RP Flex with Smart Assist
NCT06637644
Recruiting
To capture observational data of the Abiomed Impella RP Flex in a real-world setting.
Gender:
ALL
Ages:
All
Trial Updated:
10/09/2024
Locations: The Lindner Research Center at the Christ Hospital, Cincinnati, Ohio
Conditions: Right Ventricular (RV) Dysfunction
Register for Updates
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
NCT06209619
Recruiting
This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal response early on to CAR T-cell therapy. Immunotherapy with CC-99282 may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent, Primary Mediastinal Large B-Cell Lymphoma-Recurrent, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory, Diffuse Large B-Cell Lymphoma-Refractory, Follicular Lymphoma-Refractory, High Grade B-Cell Lymphoma-Refractory, Primary Mediastinal Large B-Cell Lymphoma-Refractory, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory
Register for Updates
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
NCT04039464
Recruiting
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
10/09/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Pediatric Pulmonary Hypertension
Register for Updates
A Low-Insulinemic Dietary Intervention to Reduce Breast Cancer Risk in High-Risk Women
NCT06635005
Recruiting
This clinical trial tests whether a new dietary pattern that consists of foods that lower the blood insulin response can reduce breast cancer risk in high-risk women. In a large group of patients, this new dietary pattern was associated with reduced risk of multiple cancers and reduced risk of long-term weight gain. Parts of this new dietary pattern are quite different from typical dietary recommendations, and much education is needed. Overall, compared to the typical American diet, this new die... Read More
Gender:
FEMALE
Ages:
45 years and above
Trial Updated:
10/08/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Feasibility Pilot Study, Compliance
Register for Updates
Nature IDEAS Study: an RCT to Increase Time Spent in Nature Among University Students
NCT06633367
Recruiting
This project will first examine nature opportunities, belonging and benefits with a multi-state nature-based intervention with a focus on students of color. In light of the syndemic, 'nature deficit disorder' and poor mental health, the investigators anticipate several far-reaching impacts that will (a) test a nationally useful standardized way to quantify exposure; (b) invest in nature resources and accessibility on campuses; and (c) promote the mental health and therapeutic benefits of nature... Read More
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
10/08/2024
Locations: Cleveland State University, Cleveland, Ohio
Conditions: Mental Health
Register for Updates
Open Versus Arthroscopic Stabilization of Shoulder Instability with Subcritical Bone Loss: the OASIS Trial
NCT04809064
Recruiting
This clinical trial will investigate the effects of three surgical procedures and the associated post-operative rehabilitation to optimize time to return to military duty, work and sports, and patient-reported physical function for military personnel and civilians with traumatic anterior shoulder instability and 10-20% glenoid bone loss.
Gender:
ALL
Ages:
Between 17 years and 50 years
Trial Updated:
10/08/2024
Locations: Ohio State University, Wexner Medical Center, Columbus, Ohio
Conditions: Shoulder Dislocation, Glenohumeral Dislocation, Anterior Shoulder Dislocation
Register for Updates
RASopathy Biorepository
NCT04395495
Recruiting
The RASopathies are a group of developmental disorders caused by genetic changes in the genes that compose the Ras/mitogen activated protein kinase (MAPK) pathway. New RASopathies are being diagnosed frequently. This pathway is essential in the regulation of the cell cycle and the determination of cell function. Thus, appropriate function of this pathway is critical to normal development. Each syndrome in this group of disorders has unique phenotypic features, but there are many overlapping feat... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/08/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: RAS Mutation, Neurofibromatosis 1, Noonan Syndrome, Noonan Syndrome With Multiple Lentigines, Noonan Neurofibromatosis Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Legius Syndrome, Smith-Kingsmore Syndrome, SYNGAP1-Related Intellectual Disability, DLG4, MAPK1 Gene Mutation, MTOR Gene Mutation, GATOR-1 Gene Mutation
Register for Updates
Family Navigation to Improve ADHD Treatment Adherence for Minority Children
NCT04591951
Recruiting
ADHD is the most common pediatric neurodevelopmental disorder and is associated with significant long-term impairments. Current guidelines recommend stimulant medication and/or behavioral therapy as first-line treatments for ADHD. Despite evidence that consistent treatment is important for effectively managing ADHD symptoms, treatment adherence remains suboptimal and is especially problematic among minority children. Hypothesized reasons for racial/ethnic disparities in ADHD treatment include un... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Attention Deficit Hyperactivity Disorder
Register for Updates
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
NCT04065438
Recruiting
This multicenter, prospective, single-arm clinical study will evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient has post-renal transplant recurren... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
10/07/2024
Locations: Akron Children's Hospital, Akron, Ohio
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
NCT03975231
Recruiting
This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
Register for Updates
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT03295981
Recruiting
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Giant Cell Tumor of Bone
Register for Updates
A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors
NCT06630429
Recruiting
We propose to conduct a pilot study evaluating baseline and on-treatment changes in tumor fraction (TFx) in peripheral blood in patients with NSCLC and RCC being treated with checkpoint inhibitor therapy as part of standard of care. The primary objective of the study is to determine whether baseline TFx can be reliably predicted in patients with NSCLC and RCC and if changes can be detected during treatment that may correlate with response. Exploratory analyses will be completed to assess the pot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Register for Updates